September 16th 2024
Your daily dose of the clinical news you may have missed.
September 11th 2024
EASD 2024: New data shows survodutide may be beneficial for persons with obesity and MASH.
September 10th 2024
September 9th 2024
Once-daily oral TERNS-601 was associated with a significant mean 5% weight reduction after 28 days and had a favorable tolerability profile.
ADA Standards of Care in Diabetes 2024: A Guideline Topline
For primary care clinicians, this Guideline Topline provides a summary of 2024 ADA Standard of Care updates that may support improved outcomes in your practice.
Dapagliflozin Approved by FDA to Improve Glycemic Control in Children, Adolescents with T2D
Among youth aged 10 to 17 years with uncontrolled hyperglycemia dapagliflozin led to a statistically significant reduction in A1c vs placebo in the T2NOW phase 3 clinical trial.
ADA 84th Scientific Sessions Preview: STEP-HFp-EF Trial Data, Tirzepatide for Obesity-Related OSA, Optimizing Diabetes Care in Primary Care
Find details on optimizing diabetes care in primary care settings, benefits of GLP-1RAs for patients with HF and diabetes, and tirzepatide use for obesity-related OSA.
Tirzepatide Superior to Placebo in MASH Resolution, Fibrosis Improvement: Daily Dose
Type 1 Diabetes in Older Adults Nearly Tripled in 3 Decades, According to New Data
Global prevalence of adults 65 years and older with T1D increased 180% in the past 30 years, researchers reported.
Tirzepatide Found Superior to Placebo in MASH Resolution, Fibrosis Improvement
More than 50% of patients with MASH receiving 1 of 3 doses of tirzepatide achieved MASH resolution without worsening of fibrosis vs placebo, according to data from phase 2 study.
Two Medication Classes Reduce CV, Liver Events in Persons with T2D, MASLD: Daily Dose
Abbott Secures FDA Clearance for OTC CGMs for General Public, Adults with T2D Who do not Use Insulin
Abbott becomes the second company to receive FDA clearance for an over-the-counter continuous glucose monitoring system.
BMI Affirmed as Good Screening Tool for Youth With Elevated Adiposity: Daily Dose
The GLP-1RA Pipeline is Full - Here's What to Expect
There are lots of products in development for weight loss and to treat other metabolic diseases which means more options for more people.
Semaglutide Significantly Reduces Risk of Renal Events, MACE, Death in Persons with CKD, T2D: Daily Dose
GLP-1RAs, SGLT-2 Inhibitors Tied to Lower Adverse Cardiovascular and Liver Events in Persons with T2D, MASLD
ENDO 2024. New findings suggest GLP-1RAs and SGLT-2is may be more beneficial than other diabetes agents for patients with T2D and MASLD.
BMI is Still a Reliable Screening Tool for Youth with Elevated Adiposity, Study Affirms
Despite its limitations for use in other populations, a high BMI proved a very good predictor of dangerous fat mass index in youth aged 8 to 19 years in this study.
Endocrine Society Releases New Clinical Guideline on Vitamin D Supplementation for Prevention of Disease
ENDO 2024. The expert panel suggests children, pregnant persons, adults aged ≥75 years, and adults with prediabetes consume more vitamin D than the recommended daily allowance.
Ultraprocessed Foods Raise Risk for Cardiometabolic Issues in Children: Daily Dose
New Online Tracker May Help Patients Find GLP-1RA Medication More Easily
The interactive tool provides clinicians and patients a real-time look at GLP-1RA availability.
Obesity and Mental Health: Expert Details Interplay, How the Sexes Differ
Shagun Bindlish, MD, discusses the complex interplay between obesity and mental health conditions and how sex is a potential moderating factor.
Semaglutide Significantly Reduces Risk of Renal Events, MACE, Mortality in People with CKD, T2D in Final FLOW Trial Findings
The pluripotent GLP-1 mimetic reduced risk for renal disease endpoints by 24% and MACE by 18% plus significantly retarded decline in eGFR vs placebo, study authors reported.
Ultraprocessed Foods Raise Risk for Cardiometabolic Issues in Children, According to New Research
Findings underscore a need for public health initiatives to educate vulnerable populations on cardiometabolic risks, researchers report.
GLP-1RAs Linked to Lower Risk for Cirrhosis in Patients with MASLD, Type 2 Diabetes: Daily Dose
Once-a-Week Insulin Matches Daily Insulin in Lowering HbA1c: Daily Dose
Risk of Diabetes-related Complications Higher in Men than Women: Daily Dose
GLP-1 Agonists Reduce Risk of Cirrhosis, HCC in Adults with MASLD and T2D
DDW 24. New research shows patients with MASLD and T2D who used GLP-1 agonists had a reduced risk of progression to cirrhosis and HCC vs non-users.
Irregular Menstrual Cycle Linked to Cardiometabolic Conditions Regardless of PCOS Status: Daily Dose
New Study Shows Men with Diabetes Have Higher Risk of Disease-related Complications than Women
Men with diabetes had a greater risk of CVD, lower limb and kidney complications, and diabetic retinopathy compared to women with diabetes.
Roche Says Investigational Once-Weekly "Twincretin" Shows Promise in Adults with Obesity in Early Stage Clinical Trial
In the phase 1b trial, treatment with once-weekly subcutaneous CT-388 led to a statistically significant mean placebo-adjusted weight loss of nearly 20%.
Cardiovascular-Kidney-Metabolic Syndrome in the US: Daily Dose
Lilly's Once-A-Week Insulin Demonstrates Safety, HbA1c Lowering Consistent with Daily Insulin
Safety and HbA1c reduction with efsitora alfa dosed once weekly was comparable to both daily insulin degludec and daily insulin glargine, announced Lilly.
Irregular Menstrual Cycle Associated with Cardiometabolic Conditions in Women Regardless of PCOS Status
New research shows that menstrual irregularity is associated with a higher prevalence of cardiometabolic conditions in women, even in the absence of PCOS.
Semaglutide Supports Long-Term Weight Loss, Reduces CV Risk Across BMI Subgroups
Analyses of the SELECT trial found mean weight loss of 10.2% sustained for 4 years and comparable CV benefit with weight loss greater or less than 5%, or even weight gain.